Publication: First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment
Loading...
Program
relationships.isAuthorOf
Author
Ozaras, Resat
Mete, Bilgul
Ceylan, Bahadir
Ozgunes, Nail
Gunduz, Alper
Karaosmanoglu, Hayat
Cagatay, Atahan
Gokturk, Kadir
Erdem, Levent
Kocak, Funda
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.
Description
Source
Keywords
Keywords
Citation
Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., Cagatay A., Gokturk K., Erdem L., Kocak F., et al., -First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment-, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014